- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
International Paper's hostile takeover bid for Temple-Inland shows that deal-hungry manufacturers are racing to pursue M&A before interest rates rise.
Peru votes a leftist presidential candidate into office, and Wall Street sells off mining stocks with Peruvian exposure.
Dry-bulk shippers have found themselves in a world of hurt. How did it happen, and when will it end?
Morgan Stanley's private-equity arm goes contrarian, agreeing to invest $50 million in Yongye International amid a raft of fraud scandals among Chinese small caps.
The former CFO of Crazy Eddie, the fraudulent electronics retailer from the 1980s, has transformed himself from a felon into a fraud buster and an adviser to the FBI and SEC. But don't call him an angel.
North American steel prices have declined sharply in recent weeks, making the outlook for second-half earnings that much murkier.
Con artists in the C-suite have used the same types of accounting fraud for eons. Here's what investors should know about the methods of the corporate crook.
The former CFO of Crazy Eddie, the notoriously fraudulent electronics retailer from the 1980s, has transformed himself from a felon into a fraud buster and an advisor to the FBI and the SEC. But don't call him an angel.
Fund manager Ejnar Knudsen hunts for food and agriculture equities that lie outside the mainstream.
Mosaic takes another step toward cutting ties with its one-time parent, Cargill.